Skip to main content
main-content
Top

25-05-2021 | FDA | News

approvalsWatch

FDA approves amivantamab for advanced NSCLC with EGFR exon 20 insertions

Author: Hannah Kitt

share
SHARE
print
PRINT
insite
SEARCH

medwireNews: Amivantamab-vmjw has been granted accelerated approval by the US FDA for use in patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations after prior platinum-based chemotherapy.

The FDA also approved the Guardant360® CDx assay (Guardant Health Inc, Redwood City, California, USA) as a companion diagnostic test to detect the insertions.

The decision is based on results of the phase 1 CHRYSALIS trial, which showed an overall response rate of 40% and a median duration of response of 11.1 months with the EGFR- and MET-targeted bispecific antibody in this patient population.

The recommended amivantamab dose for patients with a bodyweight below 80 kg at treatment initiation is 1050 mg once a week for 4 weeks then once every 2 weeks, and is 1400 mg on the same schedule for patients who weigh 80 kg or more.

medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group

share
SHARE
print
PRINT

2022 ASCO Annual Meeting coverage

Access the latest news and expert insight from the 2022 ASCO Annual Meeting